Thread: immunotherapy targeting alpha synuclein, tau and TDP-43
View Single Post
Old 01-07-2011, 11:34 AM
olsen's Avatar
olsen olsen is offline
Senior Member
  
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default immunotherapy targeting alpha synuclein, tau and TDP-43
Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs

http://www.drugsfreelist.com/medical...sease_Programs
Date: 05 Jan 2011


Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs.

The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson`s disease, Alzheimer`s disease and amyotrophic lateral sclerosis (ALS).
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Conductor71 (01-26-2011)